Anti-PD-1/PD-L1
PreclinicalSmall molecule
Anti-PD-1/PD-L1 is one of 31 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Preclinical.
1
Indications
4
Total Trials
2
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
797 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Ibrance
PfizerPreclinical
Viread
GileadPreclinical
Sovaldi
GileadPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Hepsera
GileadPreclinical
Coreg
Akero TherapeuticsPreclinical
Vermox
WWim Janssens
Preclinical
Miraclid
TTechpool Bio-Pharma Co., Ltd.
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Opdivo
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma1 trial
Advanced/Metastatic Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-PD-1/PD-L1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SShanghai Zhongshan Hospital